FibroGen Shares Are Trading Lower After the Company's Phase 3 Trial of Pamrevlumab Did Not Meet Its Primary Endpoint.
在该公司的Pamrevlumab第三阶段试验未达到其主要终点之后,FibroGen股价走低。
FibroGen Shares Are Trading Lower After the Company's Phase 3 Trial of Pamrevlumab Did Not Meet Its Primary Endpoint.
在该公司的Pamrevlumab第三阶段试验未达到其主要终点之后,FibroGen股价走低。
使用浏览器的分享功能,分享给你的好友吧